Our researchers also published 314 reviews and editorial articles, which underscores the high level of international leadership of our researchers.
Of more than 1,100 original articles published, almost 350 (31%) were in first-decile journals and 170 (16%) in top journals (impact factor over 10). The major strength of IDIBAPS continues to be the intense and excellent scientific production of its researchers, who in 2018 have maintained the high level reached in previous years. In addition, we compiled all the documents requested by Fundación Científica de la Asociación Española Contra el Cáncer (FC-AECC) to obtain the new accreditation as a recognized center in Cancer Research. This year, the Direction and Administration of IDIBAPS also made an extra effort to provide all the key performance Indicators (KPIs) required by the Instituto de Salud Carlos III Health Institute (ISCIII) to renew our accreditation as. The SAB is instrumental in guaranteeing the high standards in the scientific goals of the Institute. We are extremely grateful to all of them for their contributions to the success of IDIBAPS.
#FABIOLA ANSOTEGUI BLANC FULL#
We welcome Prof Amparo Cano, Full Professor of the Autonomous University of Madrid and researcher at the Institute of Biomedical Research Alberto Sols, and Dr Pura Muñoz, ICREA researcher at Pompeu Fabra University, as new members of the SAB,replacing Dr Guadalupe García-Tsa, Roberto Grozman, Bartolome Celli and Miguel Ángel Pozo. This year, the Board of Governors accepted the nomination of Prof José María Mato as new President of the Scientific Advisory Board (SAB), replacing Prof Jesús Ávila, who remains as member of the SAB. Next year will be crucial for the institutional fusion of IDIBAPS and Fundació Clínic per a la Recerca Biomèdica (SUMA project), which should facilitate research in the Clínic Barcelona Campus. We need to reinforce innovation and technology translation to attain the highest impact in clinical practice and optimize the resources to achieve the desired objectives. Major effort will be dedicated to consolidating and improving excellence in translational research, attracting and retaining talent, particularly with the crucial task of generational renewal and the need to promote the clinician scientist career. An analysis of the current situation of biomedical research and the social and scientific challenges that we all face have led us to define the strategic objectives and actions that will serve as a roadmap for addressing the complex situation in which we work. From the institutional perspective, I would like to highlight the work to culminate our new strategic plan ( ), which was discussed by a broad representation of the research and management communities. Our commitment to society stimulates us to spread this knowledge and these values to citizens of all ages.
Our scientific contributions are improving the understanding of the diseases we study and are changing the way we practice medicine. 8 ANNUAL SCIENTIFIC REPORT 2018 FOREWORD IDIBAPS Patricia Soléĩ Director s foreword It is a great privilege and satisfaction to present in this 2018 Annual Report the activities and outstanding achievements of all the people working at IDIBAPS.
0 kommentar(er)
